Successfully Entered More Than Half of the 20 Middle Eastern (MENA) Countries
Daewoong Pharmaceutical's high-purity, high-quality botulinum toxin Nabota is rapidly expanding its influence in the Middle East, which is emerging as a key market for aesthetics and plastic surgery.
Daewoong Pharmaceutical announced on the 29th that it has recently signed consecutive export contracts with Iraq and Bahrain, completing its entry into 10 out of 20 countries in the Middle East and North Africa (MENA) region.
Daewoong Pharmaceutical has recently designated the Middle East as a new strategic region for Nabota and is targeting the market at the fastest pace among domestic companies. Starting with the United Arab Emirates in 2020, Nabota has been launched in five countries, including Saudi Arabia, Qatar, T?rkiye, and Egypt. The company has signed export contracts and obtained product approvals in all five countries, marking the broadest presence among domestic companies in the region.
According to an OECD survey, the Middle East has a young population structure, with more than half of its population under the age of 30. Despite religious restrictions, beauty and plastic surgery trends are rapidly spreading among young people through social media, making the region one of explosive growth potential.
According to market research firm Grand View Research, the Middle East and North Africa aesthetics and plastic surgery market was valued at 2.5893 billion dollars (approximately 3.6286 trillion won) last year, and is expected to grow at an average annual rate of 10.7% to reach 4.7626 billion dollars (about 6.6743 trillion won) by 2030.
Daewoong Pharmaceutical plans to establish a "win-win-win" model that ensures satisfaction for the company, medical professionals, and consumers alike. Through its systematic training programs and academic support for medical professionals, Daewoong Pharmaceutical aims to enhance the procedural capabilities of healthcare providers in the Middle East, ultimately improving the quality of aesthetic and plastic surgery services experienced by patients.
In fact, last April, Daewoong Pharmaceutical invited a large group of Middle Eastern medical professionals to its global training program, the Nabota Master Class (NMC). Later this year, the company will host the first-ever "NMC MENA" in Saudi Arabia, moving the event to a global stage. Approximately 100 medical professionals from the Middle East are expected to attend, where they will acquire systematic procedural know-how and share the latest insights, making the event a global platform for academic exchange.
Yoon Junsu, Head of the Nabota Business Division at Daewoong Pharmaceutical, stated, "Nabota is successfully expanding its presence in the Middle East and North Africa based on its proven, differentiated quality in major global markets. As the region is a key hub in our global expansion strategy, we will further strengthen our efforts to establish Nabota as the leading premium toxin brand in the Middle East."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
